Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPR003
MIFTS: 48

Heparin-Induced Thrombocytopenia

Categories: Rare diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Heparin-Induced Thrombocytopenia

About this section

MalaCards integrated aliases for Heparin-Induced Thrombocytopenia:

Name: Heparin-Induced Thrombocytopenia 53 59 73
Hit 53 59
Heparin-Induced Thrombocytopenia Type 2 59
Heparin-Associated Thrombocytopenia 59
Hat 59

Characteristics:

Orphanet epidemiological data:

59
heparin-induced thrombocytopenia
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA3325
UMLS via Orphanet 74 C0272285
ICD10 via Orphanet 34 D69.5
UMLS 73 C0272285
Sources

Summaries for Heparin-Induced Thrombocytopenia

About this section
NIH Rare Diseases : 53 Heparin-induced thrombocytopenia (HIT) is an adverse reaction to the drug heparin resulting in an abnormally low amount of platelets (thrombocytopenia). HIT is usually an immune response which typically occurs 4-10 days after exposure to heparin; it can lead to serious complications and be life-threatening. This condition occurs in up to 5% of those who are exposed to heparin. Characteristic signs of HIT are a drop in platelet count of  greater than 50% and/or the formation of new blood clots during heparin therapy.  The first step of treatment is to discontinue and avoid all heparin products immediately. Often, affected individuals require another medicine to prevent blood clotting (anticoagulants).

MalaCards based summary : Heparin-Induced Thrombocytopenia, also known as hit, is related to catastrophic antiphospholipid syndrome and thrombocytopenia due to platelet alloimmunization. An important gene associated with Heparin-Induced Thrombocytopenia is F3 (Coagulation Factor III, Tissue Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Heparin and Certoparin have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and heart, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 76 Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count),... more...

Sources

Related Diseases for Heparin-Induced Thrombocytopenia

About this section

Diseases related to Heparin-Induced Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 catastrophic antiphospholipid syndrome 30.7 CD40LG F3
2 thrombocytopenia due to platelet alloimmunization 30.4 CD40LG SELP
3 coronary thrombosis 30.4 F3 SERPINC1
4 sagittal sinus thrombosis 30.3 F3 SERPINC1
5 budd-chiari syndrome 30.3 F3 SERPINC1
6 qualitative platelet defect 30.3 F3 SELP
7 marantic endocarditis 30.1 F3 SERPINC1
8 thrombotic thrombocytopenic purpura 30.0 F3 SELP
9 protein s deficiency 29.9 F3 SERPINC1
10 mitral valve stenosis 29.8 SELP SERPINC1
11 disseminated intravascular coagulation 29.7 F3 SERPINC1
12 endocarditis 29.6 FCGR2A SERPINC1
13 pulmonary embolism 29.6 F10 F3 SERPINC1
14 acute myocardial infarction 29.6 F3 SELP SERPINC1
15 purpura 29.6 CD40LG F3 SERPINC1
16 thrombophilia due to thrombin defect 29.4 F10 F3 SERPINC1
17 thrombosis 29.3 F10 F3 SELP SERPINC1
18 thrombocytosis 29.2 F3 SELP SERPINC1
19 stroke, ischemic 29.2 F3 SELP SERPINC1
20 systemic lupus erythematosus 28.5 CD40LG F3 FCGR2A
21 antiphospholipid syndrome 27.8 CD40LG F10 F3 SELP SERPINC1
22 myocardial infarction 27.4 CD40LG F10 F3 SELP SERPINC1
23 thrombocytopenia 11.3
24 hantavirus pulmonary syndrome 10.5 CD40LG F3
25 splenic disease 10.5 CD40LG F3
26 caffey disease 10.4 CD40LG F3
27 endocardium disease 10.4 CD40LG F3
28 scrub typhus 10.4 CD40LG F3
29 cerebritis 10.3
30 intestinal impaction 10.3 F3 SERPINC1
31 primary thrombocytopenia 10.3 CD40LG SELP
32 giant hemangioma 10.3 F3 SERPINC1
33 blue toe syndrome 10.3 F3 SERPINC1
34 intracranial embolism 10.3 F3 SERPINC1
35 ehrlichiosis 10.3 CD40LG SELP
36 severe hemophilia a 10.3 F3 FCGR2A
37 angina pectoris 10.3 F3 SERPINC1
38 purpura fulminans 10.2 F3 SERPINC1
39 inherited blood coagulation disease 10.2 F3 SERPINC1
40 intracranial thrombosis 10.2 F3 SERPINC1
41 hepatic infarction 10.2 F3 SERPINC1
42 syphilitic meningitis 10.2 CD40LG SERPINC1
43 thrombasthenia 10.2 F3 SELP
44 prothrombin deficiency 10.2 F3 SERPINC1
45 peripheral vertigo 10.2 F3 SERPINC1
46 japanese spotted fever 10.2 CD40LG SERPINC1
47 factor xii deficiency 10.2 F3 SERPINC1
48 aneurysm 10.2
49 pulmonary immaturity 10.2 F3 SERPINC1
50 hepatic vascular disease 10.2 F3 SERPINC1

Graphical network of the top 20 diseases related to Heparin-Induced Thrombocytopenia:



Diseases related to Heparin-Induced Thrombocytopenia
Sources

Symptoms & Phenotypes for Heparin-Induced Thrombocytopenia

About this section

MGI Mouse Phenotypes related to Heparin-Induced Thrombocytopenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 SELP SERPINC1 CD40LG F10 F3
2 hematopoietic system MP:0005397 9.55 FCGR2A SELP SERPINC1 CD40LG F3
3 immune system MP:0005387 9.35 FCGR2A SELP SERPINC1 CD40LG F3
4 mortality/aging MP:0010768 9.1 SELP SERPINC1 CD40LG F10 F3 FCGR2A
Sources

Drugs & Therapeutics for Heparin-Induced Thrombocytopenia

About this section

Drugs for Heparin-Induced Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
2 Certoparin Approved, Investigational Phase 4
3
Bivalirudin Approved, Investigational Phase 4,Phase 3 128270-60-0 16129704
4 Fondaparinux Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104993-28-4
5
Tinzaparin Approved Phase 4 9005-49-6, 9041-08-1 25244225
6
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6
7
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
8
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
9 Nadroparin Approved, Investigational Phase 4 9041-08-1
10
Argatroban Approved, Investigational Phase 4,Phase 3,Phase 2 74863-84-6 152951
11
Desirudin Approved Phase 4,Phase 2,Phase 3 120993-53-5
12
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2
13
Lepirudin Approved Phase 4 120993-53-5, 138068-37-8 16132441
14
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
15 calcium heparin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Heparin, Low-Molecular-Weight Phase 4,Phase 3,Phase 2,Phase 1
20 Hirudins Phase 4,Phase 3,Phase 2
21 Thromboplastin Phase 4,Phase 3,Phase 2
22 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 PENTA Phase 4,Phase 3,Phase 2,Phase 1
24 Antibodies Phase 4,Phase 3,Phase 1
25 Immunoglobulins Phase 4,Phase 3,Phase 1
26 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Antithrombin III Phase 4,Phase 3,Phase 2,Phase 1
29 Antithrombins Phase 4,Phase 3,Phase 2,Phase 1
30 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
32 Liver Extracts Phase 4
33 Platelet Factor 4 Phase 4,Not Applicable
34
Bilirubin Phase 4 635-65-4 5280352
35 Coagulants Phase 4
36
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
37
Rivaroxaban Approved Phase 3,Phase 2 366789-02-8
38
Ethanol Approved Phase 3 64-17-5 702
39 tannic acid Approved, Nutraceutical Phase 3
40 Kava Approved, Investigational, Nutraceutical Phase 2, Phase 3 9000-38-8
41
Creatine Approved, Investigational, Nutraceutical Phase 2, Phase 3 57-00-1 586
42
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
43 Central Nervous System Depressants Phase 3
44 Pharmaceutical Solutions Phase 3
45 Anti-Infective Agents Phase 3
46 Anti-Infective Agents, Local Phase 3
47 Citrate Nutraceutical Phase 3
48
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
49
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
50 Albumin-Bound Paclitaxel Phase 2

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 The HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Unknown status NCT02355873 Phase 4
3 Impact of Heparin on the Need for Mechanical Ventilation in Neonates Unknown status NCT00196469 Phase 4 heparin
4 Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Completed NCT00759083 Phase 4 bivalirudin
5 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
6 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
7 Nadroparin for the Initial Treatment of Pulmonary Thromboembolism Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
8 Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin Completed NCT00622648 Phase 4 Enoxaparin;Placebo
9 EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
10 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis Completed NCT00913133 Phase 4 Desirudin
11 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
12 Maintaining Patency in Implanted Port Catheters Recruiting NCT02354118 Phase 4
13 Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy Recruiting NCT01828697 Phase 4 Low dose nadroparin;Intermediate dose nadroparin;Low dose enoxaparin;Intermediate dose enoxaparin;Low dose dalteparin;Intermediate dose dalteparin;Fixed low dose tinzaparin;Intermediate dose tinzaparin
14 A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome Terminated NCT00787332 Phase 4 Desirudin or Argatroban®
15 Argatroban Versus Lepirudin in Critically Ill Patients Terminated NCT00798525 Phase 4 Argatroban;Lepirudin
16 Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion Terminated NCT01246011 Phase 4 Argatroban and warfarin
17 Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes Terminated NCT02923830 Phase 4 Saline-only catheter flush
18 Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) Withdrawn NCT00603824 Phase 4 fondaparinux;argatroban or lepirudin
19 Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) Unknown status NCT00073580 Phase 3 Angiomax (bivalirudin) anticoagulant
20 Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study Unknown status NCT00474591 Phase 3 Fondaparinux
21 Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia Completed NCT00198588 Phase 3 argatroban
22 Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning) Completed NCT00043940 Phase 3 bivalirudin
23 Angiomax in Patients With HIT/HITTS Type II Undergoing CPB Completed NCT00079508 Phase 3 Angiomax (bivalirudin)
24 Heparin 100U/L for Prevention of PVC Complications Completed NCT01131754 Phase 3
25 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed NCT00182143 Phase 3 LMWH (Fragmin, dalteparin);Unfractionated Heparin
26 The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients Completed NCT00531843 Phase 2, Phase 3 fondaparinux sodium
27 PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot Completed NCT01274637 Phase 3 Dalteparin Sodium
28 Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery Completed NCT00329433 Phase 2, Phase 3 Desirudin (Iprivask™);Heparin
29 A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries Completed NCT02368314 Phase 3 Sodium Enoxaparine
30 Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT) Recruiting NCT03147638 Phase 3 Warfarin, NOAC
31 Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients Not yet recruiting NCT03083184 Phase 3 Ethanol;enoxaparin
32 Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients Suspended NCT02271295 Phase 3 Enoxaparine
33 Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Terminated NCT01598168 Phase 3 Rivaroxaban
34 Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma Terminated NCT01773083 Phase 3 unfractionated heparin;placebo
35 Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II Completed NCT00861692 Phase 2 argatroban
36 ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial Completed NCT00839826 Phase 2 Rivaroxaban (BAY59-7939);Enoxaparin
37 Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer Recruiting NCT03254511 Phase 2 Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable;Chemotherapeutic Combinations
38 Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin Recruiting NCT02501434 Phase 2 Continuous Low-Dose IV Unfractionated Heparin Infusion
39 Heparin Anticoagulation in Septic Shock Recruiting NCT03378466 Phase 2 Unfractionated heparin
40 Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Recruiting NCT02334007 Phase 1, Phase 2 LMWH: Dalteparin
41 Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial Recruiting NCT03003390 Phase 2 Enoxaparin
42 Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) Terminated NCT00673439 Phase 2 fondaparinux;warfarin
43 Heparin-Induced Thrombocytopenia Score Card Study Completed NCT00489437 Phase 1
44 Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Completed NCT00412464 Phase 1 Fondaparinux
45 Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) Unknown status NCT00946400
46 A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients Unknown status NCT00198575
47 Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure Unknown status NCT01102790
48 Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients Unknown status NCT01363193 Not Applicable Lean Body Weight-based heparin dose
49 Study on the Incidence of Early Deep Vein Thrombosis After Peripherally Inserted Central Catheter Insertion Unknown status NCT02752984
50 Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients Unknown status NCT00510432

Search NIH Clinical Center for Heparin-Induced Thrombocytopenia

Sources

Genetic Tests for Heparin-Induced Thrombocytopenia

About this section
Sources

Anatomical Context for Heparin-Induced Thrombocytopenia

About this section

MalaCards organs/tissues related to Heparin-Induced Thrombocytopenia:

41
Testes, Liver, Heart, Skin, Lung, Monocytes, Endothelial
Sources

Publications for Heparin-Induced Thrombocytopenia

About this section

Articles related to Heparin-Induced Thrombocytopenia:

(show top 50) (show all 860)
# Title Authors Year
1
A Case of Posterior Circulation Ischemic Stroke Caused by Heparin-Induced Thrombocytopenia after Detaining Hepatic Arterial Infusion Catheter. ( 29859863 )
2018
2
Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss? ( 29164662 )
2018
3
High ANTI-PF4/Heparin Antibodies Titer and Thromboses Due to Infection 9 Months After Cessation of Heparin in Hemodialyzed Patient With Heparin-Induced Thrombocytopenia. ( 29856115 )
2018
4
Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. ( 29914979 )
2018
5
Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions. ( 29421832 )
2018
6
Abciximab/Heparin During Acute Heparin-induced Thrombocytopenia: A Word of Caution (Reply). ( 29371038 )
2018
7
Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. ( 29903887 )
2018
8
Left ventricular assist device implantation after plasma exchange for heparin-induced thrombocytopenia. ( 29938391 )
2018
9
Phlegmasia Cerulea Dolens Following Heparin-Induced Thrombocytopenia. ( 29422736 )
2018
10
Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants. ( 29788841 )
2018
11
Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study. ( 29934777 )
2018
12
Heparin-induced thrombocytopenia complicating children after the Fontan procedure: Single-center experience and review of the literature. ( 29181882 )
2018
13
Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia. ( 29742374 )
2018
14
Association of Heparin-Induced Thrombocytopenia With Bacterial Infection in Trauma Patients. ( 29955756 )
2018
15
HITTING the Diagnosis: Testing for Heparin-Induced Thrombocytopenia in Cancer Patients. ( 29901688 )
2018
16
Abciximab/Heparin During Acute Heparin-Induced Thrombocytopenia: A Word of Caution. ( 29305853 )
2018
17
Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thromboses. ( 29314517 )
2018
18
Onset of type 1 diabetes mellitus and heparin-induced thrombocytopenia in a patient with Basedow's disease and idiopathic thrombocytopenic purpura: Novel combination as autoimmune polyglandular syndrome. ( 29905024 )
2018
19
Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts. ( 29703334 )
2018
20
Successful Use of Intravenous Immunoglobulin G to Treat Refractory Heparin-Induced Thrombocytopenia With Thrombosis Complicating Peripheral Blood Stem Cell Harvest. ( 29404376 )
2018
21
Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. ( 29703336 )
2018
22
A Patient With Remote Heparin-Induced Thrombocytopenia and Antiphospholipid Syndrome Requiring Cardiopulmonary Bypass: Do Current Guidelines Apply? ( 29871549 )
2018
23
Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia. ( 29185142 )
2018
24
The Use of Cangrelor and Heparin for Anticoagulation in a Patient Requiring Pulmonary Thromboendarterectomy Surgery with Suspected Heparin-Induced Thrombocytopenia. ( 29853315 )
2018
25
A novel diagnostic algorithm for heparin-induced thrombocytopenia. ( 29756276 )
2018
26
Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review. ( 29871769 )
2018
27
Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. ( 29723924 )
2018
28
Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. ( 29325985 )
2018
29
Incidence of heparin-induced thrombocytopenia in lower-extremity free flap reconstruction correlates with the overall surgical population. ( 29980457 )
2018
30
Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients. ( 29802082 )
2018
31
Evaluation of 4T's scoring system in the identification of heparin-induced thrombocytopenia in patients with mechanical circulatory support. ( 29112890 )
2017
32
Hydrophilic Polymer Embolism in the Lung as an Adverse Eventa88- Autopsy Case of Thromboembolisms in Multiple Organs Associated With Heparin-Induced Thrombocytopenia. ( 28626145 )
2017
33
Heparin-Induced Thrombocytopenia and Vascular Surgery. ( 28807578 )
2017
34
Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia: Too Good to Be True? ( 29169471 )
2017
35
Heparin-Induced Thrombocytopenia and Thrombosis: Preventing your Thrombolysis Practice from Taking a HITT. ( 29249865 )
2017
36
Activated platelet-derived and leukocyte-derived circulating microparticles and the risk of thrombosis in heparin-induced thrombocytopenia: A role for pf4-bearing microparticles? ( 28052584 )
2017
37
Effectiveness of a Laboratory Gate-Keeping Strategy to Overcome Inappropriate Test Utilization for the Diagnosis of Heparin-Induced Thrombocytopenia. ( 28750423 )
2017
38
Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism? ( 28680014 )
2017
39
Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia. ( 28672052 )
2017
40
Incidence and Outcomes of Heparin-Induced Thrombocytopenia in Patients Undergoing Vascular Surgery. ( 28864160 )
2017
41
The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia. ( 28774196 )
2017
42
IV Immunoglobulin forA Autoimmune Heparin-Induced Thrombocytopenia. ( 28889872 )
2017
43
Persistent Heparin-Induced Thrombocytopenia Treated With IVIg. ( 28889885 )
2017
44
Low dose bivalirudin anticoagulation for lung transplantation with extracorporeal membrane oxygenation in a patient with acute heparin-induced thrombocytopenia. ( 28043990 )
2017
45
Autoimmune heparin-induced thrombocytopenia. ( 28846826 )
2017
46
Heparin-Induced Thrombocytopenia in the Critically Ill Patient. ( 29253554 )
2017
47
Use of systemic bivalirudin with catheter-directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report. ( 29068112 )
2017
48
Performance of 4T score and heparin-platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer. ( 28677022 )
2017
49
The Role of Apixaban in the Treatment of Heparin-Induced Thrombocytopenia. ( 28884054 )
2017
50
Delayed Seroconversion in a Patient With Heparin-Induced Thrombocytopenia. ( 29336969 )
2017
Sources

Variations for Heparin-Induced Thrombocytopenia

About this section
Sources

Expression for Heparin-Induced Thrombocytopenia

About this section
Search GEO for disease gene expression data for Heparin-Induced Thrombocytopenia.
Sources

Pathways for Heparin-Induced Thrombocytopenia

About this section

Pathways related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 12.64 F10 F3 SELP SERPINC1
2
Collagen chain trimerization 66
Show member pathways
 12.3 F10 F3 SERPINC1
3
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.33 F10 F3 SERPINC1
4
IL4-mediated signaling events 1
11.17 CD40LG SELP
5
Staphylococcus aureus infection 37
11.07 FCGR2A SELP
6
Complement and coagulation cascades 1 37
10.94 F10 F3 SERPINC1
7
Malaria 37
10.85 CD40LG SELP
Sources

GO Terms for Heparin-Induced Thrombocytopenia

About this section

Cellular components related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.43 CD40LG F10 F3 FCGR2A SELP SERPINC1
2 intrinsic component of external side of plasma membrane GO:0031233 8.62 F10 F3

Biological processes related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.33 F10 F3 SERPINC1
2 leukocyte cell-cell adhesion GO:0007159 9.26 CD40LG SELP
3 blood coagulation, extrinsic pathway GO:0007598 8.96 F10 F3
4 hemostasis GO:0007599 8.8 F10 F3 SERPINC1

Molecular functions related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 8.96 F10 F3
2 protease binding GO:0002020 8.62 F3 SERPINC1
Sources

Sources for Heparin-Induced Thrombocytopenia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....